<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hematopoietic support after hematopoietic cell transplantation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hematopoietic support after hematopoietic cell transplantation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hematopoietic support after hematopoietic cell transplantation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Negrin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nelson J Chao, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autologous and allogeneic hematopoietic cell transplantation (HCT) are associated with neutropenia, anemia, and thrombocytopenia in the peri-transplant period. The degree and duration of myelosuppression vary with the type of transplantation (ie, autologous versus allogeneic), preparative regimen, graft source (ie, bone marrow, peripheral blood, umbilical cord blood), and other factors. Blood product transfusions and hematopoietic growth factors are important aspects of care for the individual undergoing HCT.
        </p>
        <p>
         Hematopoietic support for the patient who undergoes autologous or allogeneic HCT is discussed in this topic.
        </p>
        <p>
         Early complications, including hematologic effects of HCT, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">
          "Early complications of hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2113469566">
         <span class="h1">
          PRIOR TO TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood product support is usually required before, during, and following hematopoietic cell transplantation (HCT) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3135280798">
         <span class="h2">
          Consultation with transfusion service
         </span>
         <span class="headingEndMark">
          —
         </span>
         The blood transfusion service should be informed of the planned transplant to prepare for special blood component needs, such as leukocyte-reduced, cytomegalovirus (CMV)-seronegative, and/or gamma-irradiated blood components. Practices applied before transplantation continue throughout the course of transplantation and beyond. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H171000342">
         <span class="h2">
          Testing of recipient and graft donor
         </span>
         <span class="headingEndMark">
          —
         </span>
         The transplant recipient and graft donor (if planning for an allogeneic HCT) require the following testing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HLA-typing
         </strong>
         – Patients should be typed for human leukocyte antigen (HLA) status to identify a compatible allogeneic graft and to select HLA-compatible blood products (eg, platelets). (See
         <a class="medical medical_review" href="/z/d/html/7922.html" rel="external">
          "Refractoriness to platelet transfusion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The role of HLA compatibility testing for allogeneic donor selection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CMV status
         </strong>
         – CMV testing should be performed for the recipient and potential allogeneic blood and graft donors. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Leukemia, chemotherapy, and HSCT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prevention of transfusion-associated CMV transmission is important for successful transplantation, as primary CMV infections increase morbidity and mortality in transplant recipients [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H876301">
         <span class="h1">
          TRANSFUSION SUPPORT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Virtually all patients undergoing transplantation require blood product support until the transplanted cells engraft sufficiently to support adequate hematopoiesis. Intensive transfusion support is often needed, especially in the face of active bleeding, infection, and other HCT-associated complications [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Transfusion services in hospitals where HCT is performed are required to have guidelines for transfusion support during the peri-transplantation period (ie, from conditioning therapy to recovery of hematopoiesis). Indications for transfusions for patients undergoing HCT resemble those for other cytopenic patients.
        </p>
        <p>
         Autologous HCT can be performed safely in patients who decline transfusion of blood products [
         <a href="#rid4">
          4
         </a>
         ]. Management of patients who decline blood transfusion for religious or other reasons is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">
          "Approach to the patient who declines blood transfusion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2622485877">
         <span class="h2">
          Duration of transfusion support
         </span>
         <span class="headingEndMark">
          —
         </span>
         The period of transfusion-requiring cytopenias varies with the type of transplant (ie, autologous versus allogeneic), preparative regimen, graft source (ie, bone marrow, peripheral blood, umbilical cord blood), medications, and transplant-associated complications.
        </p>
        <p>
         Recovery of hematopoiesis generally requires ≥14 to 21 days with bone marrow grafts, but it is faster with peripheral blood stem/progenitor cell (PBSPC) grafts, usually requiring 10 to 14 days. Compared with myeloablative conditioning (MAC), transfusion needs are generally lower in patients undergoing non-myeloablative (NMA) regimens. In a retrospective analysis, compared with MAC, fewer patients undergoing NMA transplantation required transfusions of platelets (23 versus 100 percent) and red blood cells (RBC) (63 versus 96 percent) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3984026977">
         <span class="h2">
          Leukoreduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients undergoing HCT, only leukoreduced blood products should be transfused, to reduce febrile nonhemolytic transfusion reactions (FNHTRs), alloimmunization, and transmission of infections. Use of leukoreduced blood products is standard practice for all transplant recipients.
        </p>
        <p>
         Leukoreduction refers to use of a leukocyte reduction filter to selectively remove leukocytes. This generally reduces the leukocyte count by three to four logs (99.9 to 99.99 percent) and achieves a final leukocyte count &lt;5 million/unit (&lt;5 x 10
         <sup>
          6
         </sup>
         ; the US Food and Drug Administration [FDA]-required limit) and generally &lt;1 million/unit. Leukoreduction is generally performed pre-storage, but in some cases, it can be done at the time of transfusion ("bedside").
        </p>
        <p>
         Leukoreduction decreases risks for FNHTRs, human leukocyte antigen (HLA) alloimmunization, and transmission of cytomegalovirus (CMV; which resides in WBCs) [
         <a href="#rid6">
          6
         </a>
         ]. However, leukocyte filters do not completely prevent HLA alloimmunization in all transfusion recipients, because some leukocytes and/or membrane fragments can pass through standard leukocyte reduction filters. As an example, up to 20 percent of patients in the Trial to Reduce Alloimmunization to Platelets study developed HLA antibodies, despite stringent leukocyte filtration [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3124481579">
         <span class="h2">
          Cytomegalovirus (CMV)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of post-transplant CMV infection and CMV disease is influenced by donor and recipient CMV serostatus, which must be determined prior to transplant. (See
         <a class="local">
          'Testing of recipient and graft donor'
         </a>
         above.)
        </p>
        <p>
         CMV infection is a major source of morbidity and mortality in transplant recipients, and prevention of CMV disease is important for successful HCT [
         <a href="#rid2">
          2
         </a>
         ]. Although some autologous HCT recipients reactivate latent CMV, the incidence of CMV disease in these patients is low. For allogeneic HCT, the lowest risk of post-transplant CMV is with CMV-seronegative recipients given grafts from CMV-seronegative donors. In CMV-seropositive allogeneic HCT recipients, the greatest risk for the development of CMV disease after transplant is reactivation of latent infection (rather than transfused seropositive blood). (See
         <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">
          "Prevention of viral infections in hematopoietic cell transplant recipients"
         </a>
         .)
        </p>
        <p>
         CMV seronegative and CMV seropositive patients differ in their blood product needs, as follows.
        </p>
        <p>
         CMV infection in transplanted patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">
          "Prevention of viral infections in hematopoietic cell transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2688635077">
         <span class="h3">
          CMV seronegative recipients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For CMV seronegative transplant recipients, we suggest using
         <strong>
          only
         </strong>
         seronegative blood products and graft, based on prevention of CMV infection and avoidance of adverse effects (AEs) of preventive antiviral treatments. Use of seronegative blood products in this setting is standard practice because of the severe consequences of CMV infection in this setting.
        </p>
        <p>
         We generally continue use of CMV-seronegative products for these patients until immunosuppression is withdrawn. Although leukoreduction can reduce CMV transmission, it is not an adequate substitute for CMV-seronegative blood products. However, if an urgent transfusion is needed and CMV-seronegative blood components are not adequate to meet the patient's needs, leukoreduction can reduce the risk that CMV will infect CMV-seronegative recipients [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The incidence of CMV infections is significantly decreased in transplant recipients who are CMV-seronegative and exposed only to CMV-seronegative blood products (including a seronegative graft). Avoiding the need for antiviral treatment prevents adverse effects, which can further suppress hematopoiesis or be nephrotoxic in the transplanted patient [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2234494797">
         <span class="h3">
          CMV positive recipients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For CMV seropositive transplant recipients, transfusion with either seronegative or seropositive blood products is acceptable.
        </p>
        <p>
         In CMV seropositive patients, the most common cause of CMV disease is reactivation of latent CMV (from prior exposure); use of seronegative blood products appears to have little impact on CMV reactivation. There is no direct evidence that re-infection of CMV seropositive patients can occur with a second strain of CMV from a CMV-positive graft or transfused blood product.
        </p>
        <p>
         Most transplant centers routinely administer pre-emptive antiviral treatment to seropositive recipients in whom immunocompetence is delayed. Even with pre-emptive antiviral treatment, CMV reactivation is higher in seropositive recipients who receive haploidentical; T cell–depleted; unrelated, HLA-mismatched grafts; or non-genotypically typed HLA-matched sibling grafts. (See
         <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">
          "Prevention of viral infections in hematopoietic cell transplant recipients", section on 'CMV prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1328634761">
         <span class="h2">
          Gamma irradiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all recipients of autologous or allogeneic grafts who require transfusion, we suggest using
         <strong>
          only
         </strong>
         gamma-irradiated blood products in the peri-transplantation and post-transplantation periods, based on reduced risk of transfusion-associated graft-versus-host disease (TA-GVHD).
        </p>
        <p>
         Irradiation of blood products is standard practice in the peri-transplantation and post-transplantation periods for all patients undergoing transplantation [
         <a href="#rid9">
          9
         </a>
         ]. Use of irradiated blood products should be instituted as soon as a patient is identified as a potential transplant candidate. The duration of use of irradiated products varies among centers [
         <a href="#rid10">
          10
         </a>
         ]. Some centers continue to use irradiated products indefinitely, while others continue this practice until hematological reconstitution, for a specified period (eg, six months), or until immunosuppressive medications are no longer required.
        </p>
        <p>
         Donor lymphocytes can be detected in the circulation of immunoincompetent individuals for months to years after the transfusion of freshly collected RBC or platelet components (so-called microchimerism); the lymphocytes can engraft in a susceptible immunosuppressed host and cause TA-GVHD [
         <a href="#rid11">
          11
         </a>
         ]. Gamma irradiation prevents TA-GVHD by inducing DNA crosslinks, thereby preventing proliferation of donor lymphocytes. Irradiation is the only reliable method for preventing TA-GVHD, as leukoreduction filtration methods and chemical exposures (eg, psoralens) do not completely prevent TA-GVHD [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Clinical symptoms of TA-GVHD occur between 4 and 30 days after transfusion and may include fever, maculopapular rash, bloody diarrhea, and/or pancytopenia. Although TA-GVHD is uncommon, the mortality rate is high. TA-GVHD is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7928.html" rel="external">
          "Transfusion-associated graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2818365291">
         <span class="h2">
          Iron overload
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron overload is commonly seen in patients undergoing HCT for a hematologic disorder. Such iron overload (eg, serum ferritin &gt;1000 ng/mL) may adversely affect overall survival post-HCT, increasing the likelihood of acute graft-versus-host disease, as well as the incidence of blood stream infections and sinusoidal obstruction syndrome of the liver [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p>
         Recognition and management of iron overload is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3722459678">
         <span class="h1">
          BLOOD PRODUCTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no specific guidelines for transfusion thresholds in patients undergoing HCT, but they resemble those for other cytopenic patients. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H876308">
         <span class="h2">
          Red blood cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus hemoglobin (Hb) threshold that should trigger transfusion of red blood cells (RBC). Practices vary, but many centers use Hb 7 to 8 g/dL to trigger RBC transfusion. Such a restrictive transfusion strategy is safe, effective, and may reduce transfusion-related adverse events. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Whole blood'
         </a>
         .)
        </p>
        <p>
         The transfusion threshold may be influenced by the patient's clinical condition, days since transplantation, and evidence of engraftment of other cell types, including reticulocytes. Patients with GVHD and those treated with immunosuppressive drugs, such as
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , may have continued blood product requirements due to bleeding and/or microangiopathic hemolysis.
        </p>
        <p>
         The rationale for use of leukoreduced, gamma-irradiated blood products with strict attention to CMV status of the donor and recipient is addressed above. (See
         <a class="local">
          'Transfusion support'
         </a>
         above.)
        </p>
        <p>
         Typically, type O blood is utilized if there is a major ABO mismatch between donor and recipient until engraftment of donor RBCs is confirmed. Cases of delayed hemolysis and/or pure red cell aplasia have been described in patients with pre-existing alloantibodies against Rh or ABO antigens, despite the presence of 100 percent donor chimerism of the circulating lymphocytes, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation", section on 'ABO and Rh status'
         </a>
         .)
        </p>
        <p>
         In a multicenter trial that included 300 patients undergoing autologous or allogeneic HCT for a hematologic malignancy, there was no difference in outcomes between patients who were randomly assigned to a restrictive transfusion threshold (Hb 7g/dL) versus a liberal transfusion strategy (Hb 9 g/dL) [
         <a href="#rid16">
          16
         </a>
         ]. Compared with the liberal threshold, patients treated with a restrictive strategy received fewer transfusions (2.7 versus 5.0, respectively), but there was no difference in transplant outcomes or health-related quality of life, including transplant-related mortality at day 100, length of hospital stay, intensive care unit admissions, hospital re-admissions, acute GVHD, grade ≥3 infections, or bleeding.
        </p>
        <p class="headingAnchor" id="H876315">
         <span class="h2">
          Platelets
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are severely thrombocytopenic, with or without bleeding, require platelet transfusions. We generally transfuse prophylactically for platelet counts &lt;10,000/microL and transfuse at higher values if clinical bleeding is present  (
         <a class="graphic graphic_table graphicRef115892" href="/z/d/graphic/115892.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         This approach is supported by a meta-analysis of randomized trials of prophylactic platelet transfusions versus no prophylaxis [
         <a href="#rid17">
          17
         </a>
         ] and is consistent with the 2017 American Society of Clinical Oncology (ASCO) platelet transfusion guidelines  (
         <a class="graphic graphic_table graphicRef115892" href="/z/d/graphic/115892.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ] and the 2015 AABB (formerly Association for the Advancement of Blood &amp; Biotherapies) practice guidelines [
         <a href="#rid19">
          19
         </a>
         ], as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Prevention of spontaneous bleeding'
         </a>
         .)
        </p>
        <p>
         Multicenter randomized trials that addressed platelet transfusions in the setting of HCT include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial, 400 patients undergoing autologous HCT for a hematologic malignancy or with acute leukemia were randomly assigned to receive platelet transfusions when morning platelet counts were ≤10,000/microL versus only for active bleeding [
         <a href="#rid20">
          20
         </a>
         ]. Patients transfused only for active bleeding received fewer platelet transfusions in the first 14 days (1.6 versus 2.4 transfusions per patient). Among patients undergoing HCT, there were more bleeding episodes among those transfused only for active bleeding, but most episodes were minor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the randomized TOPPS trial (Trial of Prophylactic Platelets), 600 patients with hematologic malignancies receiving chemotherapy, autologous, or allogeneic HCT were assigned to receive platelet transfusion for a platelet count ≤10,000/microL versus only for active bleeding [
         <a href="#rid21">
          21-23
         </a>
         ]. Compared with prophylactic transfusions, patients transfused only for active bleeding received fewer platelet transfusions, but had a higher incidence of major bleeding (50 versus 43 percent) and a shorter time to first bleed (1.2 versus 1.7 days) [
         <a href="#rid24">
          24
         </a>
         ]. There were no differences in duration of hospitalization and no deaths due to bleeding. In a pre-defined subgroup analysis, patients undergoing autologous HCT had similar rates of major bleeding whether they were transfused for a platelet count ≤10,000/microL or only for active bleeding (45 and 47 percent).
        </p>
        <p>
        </p>
        <p>
         Studies that compared threshold for platelet transfusion reported that, compared with patients prophylactically transfused for platelets of 20,000/microL or 30,000/microL, those transfused at 10,000/microL received increased platelet transfusions, but had only a small adverse effect [
         <a href="#rid25">
          25,26
         </a>
         ] or no effect [
         <a href="#rid27">
          27
         </a>
         ] on bleeding. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Leukemia, chemotherapy, and HSCT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H876322">
         <span class="h2">
          Granulocytes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Granulocyte transfusions are generally not used because of the lack of efficacy in clinical trials and the difficulty of obtaining sufficient cells due to the short half-life of neutrophils.
        </p>
        <p>
         There are few, if any, clinical indications for granulocyte transfusions outside of a clinical trial setting. (See
         <a class="medical medical_review" href="/z/d/html/7951.html" rel="external">
          "Granulocyte transfusions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GROWTH FACTOR SUPPORT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematopoietic growth factors (colony-stimulating factors [CSFs]) that have been evaluated in the transplant setting include granulocyte (G)-CSF, granulocyte-macrophage (GM)-CSF, erythropoietin (EPO), and thrombopoietic factors. (See
         <a class="medical medical_review" href="/z/d/html/8383.html" rel="external">
          "Introduction to recombinant hematopoietic growth factors"
         </a>
         .)
        </p>
        <p>
         Use of hematopoietic growth factors for mobilization of stem cells in donors of peripheral blood stem/progenitor cell (PBSPC) grafts, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/96033.html" rel="external">
          "Evaluation of the hematopoietic cell transplantation donor", section on 'Peripheral blood progenitor cell (PBPC) collection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3885881275">
         <span class="h2">
          G-CSF/GM-CSF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of G-CSF and GM-CSF varies according to the type of transplant.
        </p>
        <p class="headingAnchor" id="H3840566119">
         <span class="h3">
          Autologous HCT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients undergoing autologous HCT, we suggest administration of G-CSF or GM-CSF to shorten the duration of severe neutropenia, as demonstrated by a meta-analysis and randomized trials.
        </p>
        <p>
         There is no preferred agent, regimen, or route of administration. Treatment is usually begun one to five days after transplantation and continued until absolute neutrophil count (ANC) ≥10,000/microL, but a lower ANC threshold is acceptable. We consider any of the following regimens acceptable:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          G-CSF
         </strong>
         – Single dose of
         <a class="drug drug_general" data-topicid="10154" href="/z/d/drug information/10154.html" rel="external">
          pegfilgrastim
         </a>
         (6 mg) or daily
         <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">
          filgrastim
         </a>
         (5 mcg/kg/d), intravenously or subcutaneously
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GM-CSF
         </strong>
         – Daily intravenous or subcutaneous GM-CSF (250 microg/m
         <sup>
          2
         </sup>
         )
        </p>
        <p>
        </p>
        <p>
         Treatment with G-CSF or GM-CSF hastened neutrophil recovery in a meta-analysis and in multiple phase 3 trials, but only a subset of studies reported improvements in infection-associated outcomes (eg, number or severity of infections, days with fever, duration of antibiotic use) or shortened hospitalization, and none reported a difference in rates of survival or relapse. There are no reports of excess toxicity with these agents in patients undergoing autologous HCT. Informative studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meta-analysis
         </strong>
         – A 2006 meta-analysis included 34 trials of HCT that randomly assigned patients to either G-CSF or GM-CSF versus placebo/no therapy; 25 of the trials included patients undergoing autologous HCT [
         <a href="#rid28">
          28
         </a>
         ]. Treatment significantly accelerated neutrophil recovery to 500/microL (weighted mean difference [WMD] 4.0 days), reduced days of parenteral antibiotics (WMD 1.2 days), and hastened hospital discharge (WMD -2.9 days, [-3.8 to -2.1 days]); there was a trend toward fewer documented infections (relative risk [RR] 0.87 [95% CI 0.76-1.00]) with CSF treatment, but there was no impact on survival or treatment-related mortality (TRM). However, when analyzing the four trials that included only autologous HCT and reported survival data, treatment was associated with improved overall survival (OS; RR 0.89 [95% CI 0.79-0.99]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Randomized trials
         </strong>
         – Multiple randomized, placebo-controlled (or no treatment-controlled) trials in autologous HCT reported that either G-CSF [
         <a href="#rid29">
          29-32
         </a>
         ] or GM-CSF [
         <a href="#rid33">
          33-37
         </a>
         ] hastened resolution of neutropenia, but only a subset reported improvements in various infection-related outcomes, while none reported improved survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of regimen
         </strong>
         – No randomized trials have directly compared G-CSF versus GM-CSF after autologous HCT. Three randomized trials that compared
         <a class="drug drug_general" data-topicid="10154" href="/z/d/drug information/10154.html" rel="external">
          pegfilgrastim
         </a>
         versus
         <a class="drug drug_general" data-topicid="8446" href="/z/d/drug information/8446.html" rel="external">
          filgrastim
         </a>
         reported no differences in neutrophil recovery, infectious outcomes, or survival [
         <a href="#rid38">
          38-40
         </a>
         ]. Another phase 3 trial reported no difference when lenograstim (G-CSF from prepared with Chinese hamster ovary cells) was administered once daily versus split-dose administration (twice-daily) [
         <a href="#rid41">
          41
         </a>
         ]. A retrospective study reported that beginning G-CSF on the day of stem cell infusion was associated with resolution of neutropenia one day earlier than treatment beginning on day 5 [
         <a href="#rid32">
          32
         </a>
         ], but another study reported no difference between these approaches [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Allogeneic HCT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For selected patients undergoing allogeneic HCT, we suggest administration of G-CSF or GM-CSF; this includes patients who undergo non-myeloablative conditioning, receive an umbilical cord graft, are treated with post-transplant
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , or experience slow hematologic reconstitution. For others, we generally do not incorporate a CSF, given controversial data regarding adverse effects.
        </p>
        <p>
         Our approach is consistent with the 2015 American Society of Clinical Oncology guidelines on cytokine use [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Informative studies of CSFs after allogeneic HCT include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meta-analysis
         </strong>
         – The 2006 meta-analysis (described above) reported that in five randomized placebo-controlled or no treatment-controlled trials of patients undergoing allogeneic HCT, G-CSF or GM-CSF was associated with faster neutrophil recovery and fewer documented infections, but there was no effect on OS, TRM, grade 2-4 acute GVHD (aGVHD), days of parenteral antibiotics, or days to hospital discharge [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Randomized trials
         </strong>
         – Individual randomized, controlled trials in patients undergoing allogeneic HCT reported faster neutrophil engraftment, but no effect on OS or GVHD [
         <a href="#rid42">
          42-44
         </a>
         ]. A trial in children reported faster neutrophil recovery, but no increase in GVHD in recipients of allogeneic bone marrow grafts in association with G-CSF [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other studies
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A large retrospective analysis of patients transplanted with HLA-matched sibling donor grafts for acute leukemia reported that, compared with no G-CSF treatment controls, recipients of bone marrow grafts treated with G-CSF had decreased survival and increased adverse events; no such effect was reported for recipients of PBSPC grafts [
         <a href="#rid46">
          46
         </a>
         ]. For recipients of bone marrow grafts, patients treated with G-CSF had inferior OS (relative risk [RR] 0.59 [95% CI 0.46-0.75]), inferior leukemia-free survival (RR 0.64 [95% CI 0.51-0.81]), increased TRM (27 versus 17 percent; RR, 1.73 [95% CI 1.3-12.32]), increased grade 2-4 aGVHD (50 percent versus 39 percent; RR 1.33 [95% CI 1.08-1.64]), and increased chronic GVHD (cGVHD; 37 versus 28 percent; RR 1.29 [95% CI 1.02-1.61]). No such inferior effects of G-CSF were seen in patients receiving G-CSF with PBSPC grafts.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another retrospective study of allogeneic HCT, comparison of 260 patients given G-CSF versus 205 controls (no G-CSF) reported no difference in OS, non-relapse mortality, or relapse, but increased GVHD [
         <a href="#rid47">
          47
         </a>
         ]. G-CSF was associated with increased grade 2-4 aGVHD (29 versus 19 percent; hazard ratio [HR] 1.52 [95% CI 1.06-2.32]) and cGVHD (54 versus 43 percent; HR 1.51 [95% CI 1.14-2.00]). G-CSF was associated with increased aGVHD in recipients of PBSPC grafts (but not with bone marrow grafts) and increased cGVHD in recipients of bone marrow grafts (but not with PBSPC grafts).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A single-institution study of 155 patients that included 66 (44 percent) who received G-CSF reported that patients receiving G-CSF had more grade 2-4 aGVHD (34 versus 9 percent), which was independent of other risk factors for GVHD [
         <a href="#rid48">
          48
         </a>
         ]. There was no difference in OS, TRM, relapse, or cGVHD between the groups.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Erythropoietin (EPO)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients undergoing either autologous or allogeneic HCT, we suggest
         <strong>
          not
         </strong>
         routinely administering erythropoietin (EPO), based on little or no effect on red blood cell (RBC) transfusion requirements. For transplant patients, EPO is generally reserved for those with prolonged anemia (eg, RBC transfusion requirements after day 28) and for those who develop recurrent anemia after recovery of hemoglobin (Hb) level.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autologous HCT
         </strong>
         – Three randomized clinical trials reported no benefit for EPO after autologous transplantation in patients who were also treated with G-CSF; none of the trials found a significant reduction in RBC transfusion requirements [
         <a href="#rid49">
          49-52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allogeneic HCT
         </strong>
         – A placebo-controlled trial of 131 patients undergoing allogeneic HCT reported modest reductions in transfusions for patients who received EPO [
         <a href="#rid53">
          53
         </a>
         ]. There were three cohorts of patients who were randomly assigned to placebo versus EPO (500 units/kg weekly): myeloablative HCT with placebo or EPO starting on day 28; nonmyeloablative HCT with placebo versus EPO starting on day 28; or nonmyeloablative HCT with placebo versus EPO starting on day 0 [
         <a href="#rid53">
          53
         </a>
         ]. EPO was associated with fewer patients requiring transfusion (42 versus 77 percent) and fewer RBC units transfused per patient (4.1 versus 6.9 units). Patients who received EPO were also more likely to have attained Hb ≥13 g/dL by day 126 (63 versus 8 percent, median 90 days versus not reached). Among those undergoing nonmyeloablative HCT, there was no additional benefit to starting EPO at day 0 compared with starting on day 28.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A phase 3 placebo-controlled trial of 215 patients undergoing allogeneic HCT recipients reported that compared with placebo, EPO (150 units/kg per day as a continuous infusion) achieved shorter median time to transfusion independence (27 versus 19 days), but the number of transfusions was similar in the two groups [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among 91 patients randomly assigned to placebo versus EPO (300 units/kg three times weekly) after allogeneic transplantation, there was no difference in transfusion requirements, although EPO therapy was associated with increases in the reticulocyte count, Hb concentration, and bone marrow erythropoiesis on day 14 [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Post-transplant anemia is often multifactorial and may be affected by medications (eg,
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ), GVHD, and other transplant-associated conditions.
        </p>
        <p class="headingAnchor" id="H517045136">
         <span class="h2">
          Thrombopoietic growth factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no current role for thrombopoietic growth factors after either autologous or allogeneic HCT.
        </p>
        <p>
         There has been little evaluation of thrombopoietins (eg,
         <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">
          romiplostim
         </a>
         ,
         <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">
          eltrombopag
         </a>
         ) in this setting. Although generally well-tolerated, there is limited evidence that these agents accelerate platelet recovery, reduce bleeding, or lessen platelet transfusion requirements after transplantation [
         <a href="#rid55">
          55-57
         </a>
         ].
        </p>
        <p>
         Thrombopoietic agents and their clinical applications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">
          "Clinical applications of thrombopoietic growth factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H875843">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Virtually all patients undergoing autologous or allogeneic hematopoietic cell transplantation (HCT) require blood product support in the form of red blood cell (RBC) and/or platelet transfusions until the transplanted marrow cells engraft sufficiently to support hematopoiesis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior to transplantation
         </strong>
         – Important actions before transplantation include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The blood transfusion service should be informed of the planned transplant to prepare for special blood component needs. (See
         <a class="local">
          'Consultation with transfusion service'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Human leukocyte antigen (HLA) status and CMV testing should be performed for the recipient and potential allogeneic donors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusion support
         </strong>
         – The period of transfusion-requiring cytopenias varies with the type of transplant (ie, autologous versus allogeneic), preparative regimen, graft source (ie, bone marrow, peripheral blood, umbilical cord blood), medications, and transplant-associated complications. With bone marrow grafts, recovery of hematopoiesis generally requires ≥14 to 21 days, but it is faster with peripheral blood stem/progenitor cell (PBSPC) grafts (eg, 10 to 14 days).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Leukoreduction
         </strong>
         – For all patients undergoing HCT who require transfusions, we suggest use of
         <strong>
          only
         </strong>
         leukoreduced blood products, to reduce risks for febrile nonhemolytic transfusion reactions, alloimmunization, and transmission of infections (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Leukoreduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytomegalovirus (CMV)
         </strong>
         – The risk of post-transplant CMV infection and/or disease varies with CMV serostatus of the transplant recipient.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CMV seronegative recipients
         </strong>
         – For CMV seronegative transplant recipients, we suggest transfusion with
         <strong>
          only
         </strong>
         seronegative blood products to prevent CMV infection and avoid adverse effects of preventive antiviral treatments. (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (See
         <a class="local">
          'CMV seronegative recipients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CMV seropositive recipients
         </strong>
         – For CMV seropositive transplant recipients, transfusion with either seronegative or seropositive blood products is acceptable. (See
         <a class="local">
          'CMV positive recipients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gamma irradiation
         </strong>
         – For all recipients of autologous or allogeneic grafts, we suggest using
         <strong>
          only
         </strong>
         gamma-irradiated blood products in the peri- and post-transplantation period, to reduce risk of transfusion-associated graft-versus-host disease (TA-GVHD). (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (See
         <a class="local">
          'Gamma irradiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusion thresholds
         </strong>
         – Transfusion thresholds for RBCs and platelets are similar to those for other cytopenic patients. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Growth factor support
         </strong>
         – Use of hematopoietic growth factors (colony stimulating factors [CSFs]) varies with the type of transplant:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          G-CSF and GM-CSF:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Autologous
         </strong>
         – For patients undergoing autologous HCT, we suggest G-CSF or GM-CSF to shorten the duration of severe neutropenia. (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ) (See
         <a class="local">
          'Autologous HCT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Allogeneic
         </strong>
         – For select patients undergoing allogeneic HCT, we suggest G-CSF or GM-CSF; this includes patients who undergo non-myeloablative conditioning, receive an umbilical cord graft, are treated with post-transplant
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , or experience slow hematologic reconstitution (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For others, we generally do not incorporate a CSF, given controversial data regarding adverse effects. (See
         <a class="local">
          'Allogeneic HCT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Erythropoietin (EPO)
         </strong>
         – For patients undergoing either autologous or allogeneic HCT, we suggest
         <strong>
          not
         </strong>
         routinely administering erythropoietin (EPO) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Erythropoietin (EPO)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thrombopoietic growth factors
         </strong>
         – There is no demonstrated role for these factors in the post-transplant period. (See
         <a class="local">
          'Thrombopoietic growth factors'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gajewski JL, Johnson VV, Sandler SG, et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008; 112:3036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nevo S, Vogelsang GB. Acute bleeding complications in patients after bone marrow transplantation. Curr Opin Hematol 2001; 8:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck A, Lin R, Reza Rejali A, et al. Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients. Bone Marrow Transplant 2020; 55:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipson SM, Shepp DH, Match ME, et al. Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol 2001; 116:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraser GA, Walker II, Canadian Blood and Marrow Transplant Group. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant 2004; 10:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 2011; 152:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss B, Hoffmann M, Anders C, et al. Gamma-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers. Ann Hematol 2004; 83:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 1999; 93:3127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tay J, Allan DS, Chatelain E, et al. Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. J Clin Oncol 2020; 38:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anthon CT, Granholm A, Sivapalan P, et al. Prophylactic platelet transfusions versus no prophylaxis in hospitalized patients with thrombocytopenia: A systematic review with meta-analysis. Transfusion 2022; 62:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013; 368:1771.
          </a>
         </li>
         <li class="breakAll">
          A Randomised Controlled Trial of Prophylactic Vs No-Prophylactic Platelet Transfusions in Patients with Haematological Malignancies (TOPPS: Trial Of Prophylactic PlateletS) http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=3825 (Accessed on August 21, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010; 24:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon J. Stanworth, Lise Estcourt, Gillian Powter, et al. The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. American Society of Hematology abstract book 2012; 120:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia. N Eng J Med 1997; 337:1870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diedrich B, Remberger M, Shanwell A, et al. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005; 45:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dekker A, Bulley S, Beyene J, et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24:5207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klumpp TR, Mangan KF, Goldberg SL, et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demirer T, Ayli M, Dagli M, et al. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002; 118:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson JM, Carlton P, Akard LP, et al. Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization. Transfusion 2009; 49:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link H, Boogaerts MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80:2188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Advani R, Chao NJ, Horning SJ, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 116:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorin NC, Coiffier B, Hayat M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 1992; 80:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerds A, Fox-Geiman M, Dawravoo K, et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rifkin R, Spitzer G, Orloff G, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagna L, Bramanti S, Levis A, et al. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010; 21:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang G, Ko OB, Kim S, et al. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Transfusion 2008; 48:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97:3405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dallorso S, Rondelli R, Messina C, et al. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial. Haematologica 2002; 87:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringdén O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringden O, Hassan Z, Karlsson H, et al. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation 2010; 90:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remberger M, Naseh N, Aschan J, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link H, Boogaerts MA, Fauser AA, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84:3327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao NJ, Schriber JR, Long GD, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83:2823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vannucchi AM, Bosi A, Ieri A, et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 1996; 17:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol 2013; 88:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaspers A, Baron F, Willems E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. Blood 2014; 124:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggs JC, Atkinson KA, Booker V, et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995; 15:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahat U, Rotz SJ, Hanna R. Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020; 26:e65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bento L, Canaro M, Bastida JM, Sampol A. Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Med 2022; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao Y, Tang Y, Qi J, et al. Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review. Expert Rev Hematol 2021; 14:1041.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3538 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18583566" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14506657" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11604568" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acute bleeding complications in patients after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31898692" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11042658" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11447751" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9417523" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111928" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21083660" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14551741" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Gamma-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10216112" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16686840" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18762767" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19401560" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508292" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32083994" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35986657" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prophylactic platelet transfusions versus no prophylaxis in hospitalized patients with thrombocytopenia: A systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230498" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25383671" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Platelet transfusion: a clinical practice guideline from the AABB.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22877506" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23656642" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23656642" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20656185" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9060557" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15987349" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17114653" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7512124" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7538555" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12199792" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19040494" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1421390" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1345803" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1515637" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1728202" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1903847" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20045479" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20511163" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20007996" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18194384" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7581096" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10891434" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11369630" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12495901" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14691124" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20814354" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12838288" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7949088" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A controlled trial of recombinant human erythropoietin after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7514046" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8722349" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23873823" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24850754" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7742745" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31830528" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35268455" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34844489" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
